Table 3.
Results of subgroup analysis of pooled HRs of RFS of HCC patients with high APRI
| Stratified analysis | No. of studies | No. of patients | Pooled HR (95% CI) | P-value | I2(%) | PQ |
|---|---|---|---|---|---|---|
| Analysis type | ||||||
| MVA | 6 | 1,080 | 1.78 (1.39–2.16) | <0.001 | 0.0 | 0.848 |
| UVA | 3 | 1,885 | 2.07 (1.26–2.88) | <0.001 | 0.0 | 0.716 |
| Cutoff value selection | ||||||
| ROC analysis | 7 | 2,622 | 1.81 (1.42–2.20) | <0.001 | 0.0 | 0.811 |
| Others | 2 | 343 | 1.90 (1.16–2.65) | 0.001 | 0.0 | 0.832 |
| Treatments | ||||||
| No surgery | 3 | 441 | 2.03 (1.36–2.71) | <0.001 | 0.0 | 0.703 |
| With surgery | 6 | 2,524 | 1.76 (1.35–2.16) | <0.001 | 0.0 | 0.862 |
Note: Relationship between APRI and DFS in HCC.
Abbreviations: APRI, aminotransferase-to-platelet ratio index; DFS, disease-free survival; HCC, hepatocellular carcinoma; HR, hazard ratio; MVA, multivariate analysis; RFS, recurrence-free survival; ROC, receiver operating characteristic curve; UVA, univariate analysis.